GlassScriptPhysician profile
Tariq Ahmad
NPI 1104955699
$75,166.10
in general payments reported to CMS, 2019-2025
17 companies · $8,195 in 2025
The $8,195 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,123 · 2020: $12K · 2021: $274 · 2022: $4,424 · 2023: $1,668 · 2024: $42K · 2025: $8,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,200 · Travel and Lodging: $3,485 · Food and Beverage: $1,314 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,705.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,200.00 |
| Travel and Lodging | $3,484.91 |
| Food and Beverage | $1,313.89 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19,162.36 | 2024-2025 | Wegovy |
| Eli Lilly and Company | $11,810.00 | 2024 | Jardiance |
| Amgen INC. | $11,651.25 | 2019-2020 | |
| Edwards Lifesciences Corporation | $10,464.12 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $4,394.00 | 2022 | |
| Vifor Pharma, INC. | $3,790.61 | 2019 | |
| Lilly USA, LLC | $3,600.00 | 2024 | Jardiance |
| Astrazeneca Uk Limited | $3,512.31 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $2,037.85 | 2019 | |
| Abbott Laboratories | $1,636.59 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,509.03 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $1,162.85 | 2025 | Verquvo |
| Boehringer Ingelheim International Gmbh | $273.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $131.83 | 2023 | Xarelto |
| Heartflow, INC. | $29.66 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.